Hims & Hers Health (HIMS) Insider David Wells Sells 3,656 Shares

Insider Buying and Selling at Hims & Hers Health, Inc.

David Wells sold 3,656 shares of Hims & Hers Health, Inc. (NYSE: HIMS) on June 11, 2026. At the current share price of $26.82, this sale is valued at about $98,000. This transaction reflects Wells’ decision to reduce his holdings in the company, which operates in the healthcare sector.

Other Insider Activity

Several other insiders at Hims & Hers Health have also made trades recently. On June 15, Deborah Autor, the Chief Policy Officer, sold 15,396 shares valued at approximately $464,497. Chief Legal Officer Soleil Boughton sold 42,261 shares, while CTO Mohamed Elshenawy purchased 282,597 shares. Delos Cosgrove also bought 3,656 shares on the same day as Wells' sale. These activities suggest varying sentiments among the company's leadership regarding their stock positions.

How Hims & Hers Health, Inc. Stock Has Traded

Currently, Hims & Hers Health shares are trading at $26.82, which is a decrease from the previous close of $27.72. The stock has seen a 52-week range between $13.74 and $57.45. The shares are trading slightly below their 50-day moving average of approximately $29.40. This decline in price could be a point of interest for investors.

Analysts Set New Price Targets

Analysts have mixed views on Hims & Hers Health. On August 24, 2026, Truist Securities maintained a "Hold" rating with a price target of $32. Barclays also kept its "Overweight" rating with a target of $35. Other firms like Citigroup and Deutsche Bank maintained their ratings of "Neutral" and "Hold" respectively, with targets of $33 and $26. The consensus among analysts suggests a cautious outlook, with a mean target price of $31.15 based on 13 opinions.

What Hims & Hers Health, Inc. Does

Hims & Hers Health, Inc. is a healthcare platform that connects consumers with licensed healthcare professionals. The company offers a variety of health and wellness products, including prescription and over-the-counter items, through its websites and mobile applications. This recent insider trading activity may reflect the company's ongoing adjustments in response to market conditions.

What's Ahead for Hims & Hers Health, Inc.

Investors should keep an eye on the upcoming earnings report scheduled for November 9, 2026. Recent insider transactions, including those by David Wells, provide insights into the sentiments of the company’s leadership. As a reminder, this insider transaction reflects past activity and may not represent current holdings, so further filings may provide more context.